Aceto Corporation (ACET): Price and Financial Metrics


Aceto Corporation (ACET)

Today's Latest Price: $13.10 USD

0.32 (-2.38%)

Updated Jan 15 4:00pm

Add ACET to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 99 in Chemicals

See all "A" rated Strong Buy stocks

ACET Stock Price Chart Interactive Chart >

Price chart for ACET

ACET Price/Volume Stats

Current price $13.10 52-week high $21.70
Prev. close $13.42 52-week low $6.02
Day low $12.91 Volume 25,600
Day high $13.44 Avg. volume 42,650
50-day MA $13.12 Dividend yield N/A
200-day MA $13.67 Market Cap 256.77M

Aceto Corporation (ACET) Company Bio


Aceto Corporation sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The company was founded in 1947 and is based in Port Washington, New York.


ACET Latest News Stream


Event/Time News Detail
Loading, please wait...

ACET Latest Social Stream


Loading social stream, please wait...

View Full ACET Social Stream

Latest ACET News From Around the Web

Below are the latest news stories about Adicet Bio Inc that investors may wish to consider to help them evaluate ACET as an investment opportunity.

Adicet Bio to Participate in Upcoming Investor Conferences

MENLO PARK, Calif. and BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two virtual investor conferences in January. Details of the events are as follows:H.C. Wainwright Bioconnect 2021 Conference The presentation will be available for on-demand viewing starting January 11, 2021 at 6:00 AM ET.B. Riley Securities' Oncology Investor Conference Fireside chat on January 20, 2021 at 3:30 PM ET.A replay of the pre-recorded H.C. Wainwright presentation can be accessed on January 11, 2021 in the investors section of the Company’s website, and a live webcast of the B. Riley...

Yahoo | January 7, 2021

Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit

MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that Chen Schor, President and Chief Executive Officer and Stewart Abbot, Ph.D., Chief Scientific and Operating Officer, will participate in a fireside chat at The JMP Securities Hematology Summit on Tuesday, December 15, 2020 at 2:00 PM ET. A live audio webcast of the fireside chat can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.About Adicet Bio, Inc. Adicet Bio, Inc. is a biotechnology company discovering and developing a...

Yahoo | December 8, 2020

Is ACET A Good Stock To Buy Now?

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Yahoo | December 8, 2020

Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update

MENLO PARK, Calif. and BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today reported financial results for the third quarter ended September 30, 2020. “We are extremely proud of the milestones we’ve achieved this quarter, including the completion of the merger between Adicet Bio and resTORbio, the clearance of our IND application for ADI-001, and the expansion of our executive team with the appointment of Nick Harvey as CFO and, more recently, Don Healey, Ph.D., as CTO,” said Chen Schor, President and Chief Executive Officer of Adicet. “Looking ahead, we expect to initiate the Phase 1 clinical trial for ADI-001 in the first...

Yahoo | November 5, 2020

Adicet Appoints Don Healey, Ph.D., as Chief Technology Officer

MENLO PARK, Calif. and BOSTON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced the appointment of Don Healey, Ph.D., as Chief Technology Officer. Dr. Healey will lead the development of Adicet’s genetically-modified T cell therapies for clinical development and commercialization, including manufacturing, viral vector operations and analytics. “We are excited to welcome Don as a new member of Adicet’s Executive Leadership Team,” said Chen Schor, President and Chief Executive Officer of Adicet. “Don’s expertise in guiding the production and release of cell therapy products, as well as his deep knowledge of the scientif...

Yahoo | October 26, 2020

Read More 'ACET' Stories Here

ACET Price Returns

1-mo -9.53%
3-mo -1.87%
6-mo -33.16%
1-year 28.18%
3-year N/A
5-year N/A
YTD -6.76%
2020 34.71%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6852 seconds.